National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pasireotide (Signifor®)

For the treatment of adult patients with Cushing’s Disease for whom surgery is not an option or for whom surgery has failed

Rapid Review

Commenced Completed Outcome
29/03/2012 10/04/2012 Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.